Suppr超能文献

水刀消融术在既往接受过良性前列腺增生手术患者中的安全性和可行性

The Safety and Feasibility of Aquablation in Patients with Previous Surgery for Benign Prostatic Hyperplasia.

作者信息

Sanchez Desiree E, Ghoreifi Alireza, Storino Ramacciotti Lorenzo, Cai Jie, Maas Marissa, Venkat Abhishek, Lee Randall, Abreu Andre Luis, Cacciamani Giovanni E, Doumanian Leo, Gill Inderbir, Liu-Chen Andrew, Nguyen Mike, Sotelo Rene, Desai Mihir M

机构信息

USC Institute of Urology and Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

出版信息

J Endourol. 2025 Jan;39(1):50-55. doi: 10.1089/end.2024.0370. Epub 2024 Dec 6.

Abstract

Aquablation for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) has been adopted to treat a wide range of prostate anatomies including glands up to 150 cc. Patients with recurrence of LUTS after previous BPH procedure often present with variant anatomy, and a paucity of literature exists on the optimal treatment modality for these patients. Herein, we evaluate the safety and feasibility of aquablation in patients with previous BPH surgical history. A prospectively managed single institution database of aquablation patients with BPH/LUTS was queried from August 2020 to December 2022 for patients who failed previous BPH procedures. Patients were divided into two groups: those with and without previous BPH procedure. Primary outcomes were intraoperative and 90-day complications. Secondary outcomes included operative time (OT), number of Aquabeam passes, estimated blood loss, hospital length of stay, and catheter duration. Outcomes were assessed using chi-squared, Wilcoxon rank sum tests, and logistic regression. A total of 200 patients with BPH/LUTS were treated with aquablation. We identified 26 patients with a history of previous BPH procedures. Patients who underwent previous BPH procedures had smaller prostate volumes (60 cc) compared with treatment-naïve (88 cc) patients, = 0.016. There was no difference in perioperative and 90-day complications (29% for treatment-naïve 17% in the retreatment group, = 0.32). Most secondary outcomes were the same including OT, but the retreatment group had fewer Aquabeam passes (2 [1-2] 2 [2-2] treatment-naïve, = 0.037) and more additional procedures at follow-up (30% 8.3% treatment-naïve, = 0.005). Patients with previous BPH interventions remain excellent candidates for aquablation, with similar perioperative and 90-day postoperative outcomes compared with intervention-naïve patients. Aquablation demonstrates efficient tissue ablation without the risk of increased injury or significant blood loss after prior failed BPH procedures.

摘要

水刀消融术已被用于治疗因良性前列腺增生(BPH)继发的下尿路症状(LUTS),可处理各种前列腺解剖结构,包括体积达150立方厘米的腺体。既往接受过BPH手术的LUTS复发患者,其解剖结构往往存在变异,而针对这些患者的最佳治疗方式,相关文献较少。在此,我们评估水刀消融术在有既往BPH手术史患者中的安全性和可行性。2020年8月至2022年12月期间,在一个前瞻性管理的单机构BPH/LUTS水刀消融术患者数据库中,查询既往BPH手术失败的患者。患者分为两组:有和没有既往BPH手术史的患者。主要结局指标为术中及90天并发症。次要结局指标包括手术时间(OT)、水刀脉冲次数、估计失血量、住院时间和导尿管留置时间。采用卡方检验、Wilcoxon秩和检验和逻辑回归评估结局。共有200例BPH/LUTS患者接受了水刀消融术。我们确定了26例有既往BPH手术史的患者。与未接受过治疗的患者(88立方厘米)相比,既往接受过BPH手术的患者前列腺体积较小(60立方厘米),P = 0.016。围手术期及90天并发症无差异(未接受过治疗的患者为29%,再次治疗组为17%,P = 0.32)。大多数次要结局指标相同,包括OT,但再次治疗组水刀脉冲次数较少(2[1 - 2]对未接受过治疗的患者为2[2 - 2],P = 0.037),随访时额外手术更多(30%对未接受过治疗的患者为8.3%,P = 0.005)。有既往BPH干预史的患者仍是水刀消融术的理想候选者,与未接受过干预的患者相比,围手术期及术后90天结局相似。水刀消融术在既往BPH手术失败后,能有效消融组织,且无增加损伤风险或大量失血的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验